Research Area

Cardiovascular Disease Research

Cardiovascular diseases arise from interacting metabolic, inflammatory, mechanical, ischemic and genetic stresses that progressively alter the behavior of vascular and cardiac cells. Cell-based experimental systems allow researchers to separate these mechanisms, reconstruct disease-associated microenvironments and investigate how specific cell populations contribute to cardiovascular pathology.

Cardiovascular diseases remain the leading cause of death globally. The World Health Organization estimated that approximately 19.8 million people died from cardiovascular diseases in 2022, representing about 32% of global deaths.¹ Beyond this clinical burden, cardiovascular disease represents a broad biological problem involving endothelial dysfunction, vascular inflammation, smooth muscle remodeling, myocardial injury, fibrosis, abnormal metabolism and inherited defects.

Explore Research Mechanisms Choose Cell Models

A mechanism-based view

From cardiovascular stress to disease phenotype

01 Pathological Stress

Disturbed flow, lipids, cytokines, hypoxia, mechanical stress or genetic alteration

02 Cellular Response

Oxidative stress, inflammation, metabolic change, apoptosis or phenotype switching

03 Tissue Dysfunction

Vascular remodeling, plaque formation, fibrosis, ischemic damage or altered contractility

04 Research Intervention

Mechanistic investigation, target validation, drug screening and therapeutic evaluation

Research Framework

Investigating Cardiovascular Disease Through Cellular Mechanisms

Clinical categories such as atherosclerosis, hypertension, myocardial infarction, cardiomyopathy and heart failure are important endpoints, but experimental cardiovascular research often begins at an earlier biological level. Investigators ask how defined stresses alter endothelial cells, vascular smooth muscle cells, cardiomyocytes, fibroblasts, monocytes and macrophages—and how those cellular responses contribute to disease progression.

This distinction is especially important when modeling complex systemic conditions. Diabetes, chronic kidney disease, obesity and hypertension are cardiovascular risk conditions rather than single cellular mechanisms. Their cardiovascular effects can involve altered endothelial metabolism, oxidative stress, inflammatory signaling, abnormal glycation, altered lipid handling, neurohormonal activation and other processes. A recent review in Nature Reviews Cardiology, for example, describes endothelial metabolic dysfunction as a mechanism linking cardiometabolic stressors including diabetes, hypertension, obesity and chronic kidney disease with cardiovascular pathology.²

Systemic Context Metabolic, inflammatory, hemodynamic or genetic disturbance

→

Experimental Variable Defined biochemical or physical stimulus

→

Cellular Phenotype Measurable functional or molecular change

→

Disease Mechanism Contribution to vascular or myocardial pathology

Major Investigation Areas

Cellular Processes Central to Cardiovascular Research

Different cardiovascular questions require different cell types, disease-associated stimuli and experimental endpoints.

2.1

Vascular Biology

Endothelial Dysfunction & Vascular Homeostasis

Endothelial cells form the interface between circulating blood and the vessel wall. They regulate vascular tone, permeability, coagulation, leukocyte trafficking, angiogenesis and nutrient exchange. Cardiovascular disease can therefore begin before gross structural changes become visible: metabolic and mechanical disturbances may first reprogram endothelial signaling and metabolism.

Pasut and colleagues describe endothelial dysfunction as an early event in several cardiovascular disorders and highlight how disease-associated metabolic changes can precede overt clinical pathology.² Endothelial phenotype is also strongly influenced by blood flow. Arterial regions exposed to disturbed, low-magnitude and oscillatory shear stress are especially susceptible to atherosclerosis, whereas stable unidirectional flow generally promotes a more atheroprotective endothelial state.³

Research Questions

How is endothelial nitric oxide signaling altered?
What induces inflammatory endothelial activation?
How does vascular permeability change?
How do endothelial cells respond to shear stress?
What drives endothelial senescence or apoptosis?
How is angiogenic capacity altered?

Representative Models

Human aortic endothelial cells
Human coronary artery endothelial cells
Human cardiac microvascular endothelial cells
HUVECs
Organ-specific microvascular endothelial cells
Immortalized endothelial cell models

Common Readouts

eNOS / nitric oxide signaling
VCAM-1 and ICAM-1
ROS and oxidative stress
Barrier integrity and permeability
Leukocyte adhesion
Migration and tube formation

Model-selection consideration

HUVECs are widely used because they are accessible and well characterized, but they originate from a venous neonatal vessel. For questions specifically involving coronary or arterial atherosclerosis, human aortic or coronary artery endothelial cells can provide greater anatomical relevance.

2.2

Atherosclerosis

Lipid Handling, Vascular Inflammation & Foam-Cell Biology

Atherosclerosis is a multicellular process rather than passive lipid deposition. Endothelial activation facilitates recruitment of circulating monocytes; differentiated macrophages internalize modified lipoproteins; vascular smooth muscle cells undergo migration and phenotypic remodeling; and extracellular matrix composition changes as lesions progress.

Oxidized low-density lipoprotein (oxLDL) is frequently used experimentally to model atherogenic lipid stress. Depending on the cell population, oxLDL exposure can be used to investigate endothelial dysfunction, macrophage lipid accumulation, scavenger-receptor signaling and inflammatory responses. More advanced systems can combine endothelial cells, monocytes/macrophages and vascular smooth muscle cells to reproduce selected interactions within the developing vascular lesion.

01 Endothelial Activation

Disturbed flow, inflammatory signals and lipoprotein-associated stress alter endothelial phenotype.

02 Monocyte Recruitment

Adhesion molecules and chemokines facilitate leukocyte attachment and transendothelial migration.

03 Macrophage Lipid Uptake

Modified lipoprotein uptake contributes to lipid-loaded foam-cell phenotypes.

04 Vascular Remodeling

VSMC migration, proliferation, matrix deposition and phenotype switching reshape the vessel wall.

Published Experimental Example

Combining metabolic and hemodynamic stress

Patibandla and colleagues exposed human aortic endothelial cells to hyperglycemic conditions under normal or disturbed flow rather than studying elevated glucose in isolation. The combination of high glucose and disturbed flow produced greater endothelial dysfunction than high glucose under normal-flow conditions, illustrating how multiple cardiovascular stresses can be combined in vitro to create a more disease-relevant vascular niche.⁵

2.3

Vascular Remodeling

Vascular Smooth Muscle Phenotype, Remodeling & Calcification

Vascular smooth muscle cells (VSMCs) normally contribute to vascular tone and structural integrity. Unlike terminally fixed cell types, however, VSMCs display substantial phenotypic plasticity. Disease-associated conditions can shift cells away from a contractile phenotype toward proliferative, synthetic, inflammatory or osteogenic-like states.

Neurohormonal signaling is one experimental route into this process. Angiotensin II has been used to induce VSMC responses associated with hypertension and vascular dysfunction, including oxidative stress, pro-inflammatory gene expression and proliferation.⁶ Mechanical strain, cytokines and modified lipoproteins can be incorporated when different aspects of pathological remodeling are under investigation.

Vascular Remodeling

Representative experimental stimuli:

Angiotensin II Endothelin-1 Mechanical stretch Inflammatory cytokines Oxidative stress

Typical endpoints include proliferation, migration, ROS, inflammatory signaling and expression of contractile or synthetic-state markers.

Vascular Calcification

Representative experimental stimuli:

Elevated phosphate Elevated calcium Ca/P combinations Pro-calcific medium

Typical endpoints include calcium deposition, Alizarin Red staining and osteogenic-associated markers such as RUNX2, ALPL and BMP2.

Published Experimental Example

Cell-mediated vascular calcification

Reynolds and colleagues demonstrated that elevated extracellular calcium or phosphate could induce calcification in human vascular smooth muscle cells, with combined exposure producing synergistic effects. The work supported the concept that vascular calcification is an actively regulated cellular process rather than simple passive mineral precipitation.⁷

2.4

Myocardial Injury

Ischemia, Hypoxia & Reperfusion Injury

Myocardial ischemia occurs when oxygen and nutrient delivery become insufficient for cardiac demand. Restoration of blood supply is essential, but reperfusion can itself produce additional injury through rapid changes in oxygen availability, reactive oxygen species generation, mitochondrial dysfunction, calcium imbalance and cell-death signaling.

In vitro, selected components of ischemia-reperfusion injury are commonly reconstructed using hypoxia/reoxygenation or oxygen-glucose deprivation/reoxygenation systems. These models enable controlled investigation of injury kinetics and provide experimental platforms for evaluating candidate cardioprotective mechanisms.

Stage A Hypoxia / OGD

Reduced oxygen with or without glucose/serum restriction

→

Stage B Reoxygenation

Return to oxygenated culture conditions

→

Analysis Cellular Injury

Viability, LDH, ROS, apoptosis, mitochondrial and cardiac injury markers

Published Experimental Example

Optimizing a hypoxia/reoxygenation cell model

Wen and colleagues established a reproducible H9c2 hypoxia/reoxygenation injury system and evaluated cellular damage using apoptosis, LDH release, cardiac troponin release, morphology and hypoxia-associated signaling.⁸ Such models are useful for controlled mechanistic work and preliminary screening, although H9c2 cells are rat embryonic cardiac myoblast-derived cells and should not be considered equivalent to mature human cardiomyocytes.

2.5

Cardiac Remodeling

Fibroblast Activation, Myocardial Fibrosis & Heart Failure

Cardiac fibroblasts maintain the myocardial extracellular matrix under physiological conditions. Following myocardial injury or chronic mechanical and inflammatory stress, fibroblasts can transition toward activated myofibroblast phenotypes characterized by increased contractility and extracellular-matrix production.

This response is necessary for wound stabilization after acute injury, but persistent fibroblast activation can result in excessive matrix deposition, increased myocardial stiffness and adverse cardiac remodeling. TGF-β signaling is therefore frequently used as an experimental entry point for investigating cardiac fibrosis.

Stimulus TGF-β1

Cellular Transition Fibroblast → Myofibroblast

Representative Readouts α-SMA · COL1A1 · COL3A1 · Fibronectin

Published Experimental Example

Chemical and mechanical regulation of human cardiac fibroblasts

Cho and colleagues cultured primary adult human cardiac fibroblasts on substrates of different stiffness and treated the cells with TGF-β1. Although extracellular-matrix rigidity influenced early responses, TGF-β1 became the dominant regulator of myofibroblast differentiation, assessed primarily through α-smooth muscle actin expression.⁹

This type of system illustrates why fibrosis models can benefit from consideration of both soluble signaling molecules and the mechanical properties of the cellular microenvironment.

2.6

Precision Disease Modeling

Genetic Cardiovascular Disease, Engineered Models & Cardiotoxicity

Not all cardiovascular pathology begins with an externally applied stress. Cardiomyopathies, channelopathies and other inherited cardiovascular disorders may originate from disease-associated genetic variants affecting contractile proteins, ion channels, cellular metabolism or structural pathways.

Human induced pluripotent stem cells can be differentiated into cardiomyocytes, endothelial cells and vascular smooth muscle cells. Patient-derived and genetically engineered iPSC systems therefore provide opportunities to investigate disease-associated phenotypes in a defined human genetic background. Chen, Matsa and Wu reviewed the application of hiPSC-derived cardiovascular cells to cardiomyopathies, arrhythmia syndromes, vascular disorders, cardiometabolic disease and drug development.¹⁰

Genetic Disease Modeling

Gene-edited or patient-derived models can support investigation of variant-specific mechanisms, comparison with isogenic controls and evaluation of genotype-dependent drug responses.

Cardiovascular Safety

Cardiomyocytes and advanced cardiac models can be challenged with therapeutic compounds to investigate mitochondrial injury, oxidative stress, contractility, electrophysiology and treatment-associated cardiotoxicity.

Translational Example

Patient-specific susceptibility to doxorubicin cardiotoxicity

Burridge and colleagues generated hiPSC-derived cardiomyocytes from breast-cancer patients with different clinical susceptibility to doxorubicin-induced cardiotoxicity. Cardiomyocytes derived from patients who had experienced cardiotoxicity showed greater sensitivity to doxorubicin, including altered viability, mitochondrial and metabolic function, calcium handling and oxidative-stress responses.¹¹

This study illustrates how a cardiovascular cell model can move beyond reproducing general toxicity and instead investigate differences in individual disease or treatment susceptibility.

Modeling Disease-Associated Stress

From Cardiovascular Risk to Measurable Cellular Dysfunction

Systemic risk conditions can be deconstructed into experimentally controllable biochemical and physical variables.

Experimental Stress	Common Cell Models	Processes Investigated	Cardiovascular Context
High glucose	Endothelial cells, VSMCs, cardiomyocytes	ROS, metabolic stress, inflammation, apoptosis, barrier dysfunction	Hyperglycemia-associated vascular and myocardial dysfunction
Advanced glycation end products	Endothelial cells, VSMCs	AGE-RAGE signaling, oxidative stress, inflammatory activation	Chronic glycation-associated vascular injury
LDL / oxidized LDL	Endothelial cells, macrophages, VSMCs	Lipid uptake, foam-cell phenotype, inflammatory signaling	Atherogenesis
Disturbed flow	Arterial endothelial cells	Mechanotransduction, inflammatory reprogramming, endothelial phenotype	Atherosclerosis-prone vascular regions
Angiotensin II	VSMCs, endothelial cells, cardiac fibroblasts	Oxidative stress, inflammation, proliferation and remodeling	Hypertension and pathological remodeling
Elevated calcium / phosphate	Vascular smooth muscle cells	Osteogenic-like transition and mineral deposition	Vascular calcification
Hypoxia / reoxygenation	Cardiomyocytes and cardiac-derived models	ROS, mitochondrial dysfunction, apoptosis, cellular injury	Myocardial ischemia-reperfusion injury
TGF-β1	Cardiac fibroblasts	Myofibroblast differentiation and ECM deposition	Cardiac fibrosis and remodeling
TNF-α / IL-1β and other cytokines	Endothelial cells, VSMCs, immune cells	Inflammatory activation, adhesion molecules, cytokine responses	Vascular inflammation
Disease-associated genetic alteration	Engineered cells, iPSC-derived cardiovascular cells	Variant-specific signaling and cellular phenotype	Cardiomyopathy, arrhythmia and inherited disease
Cardiotoxic compounds	Cardiomyocytes, hiPSC-CMs, multicellular cardiac systems	Viability, ROS, mitochondria, calcium handling, electrophysiology	Preclinical cardiovascular safety

High glucose and AGEs represent related but different experimental questions.

Chronic hyperglycemia promotes non-enzymatic glycation and accumulation of advanced glycation end products (AGEs), but exposing cultured cells to elevated glucose is not equivalent to exposing them directly to glycated proteins or defined AGE preparations. Banarjee and colleagues used glycated human serum albumin to treat HUVECs and observed AGE-associated endothelial changes including increased oxidative stress and apoptosis, supporting an AGE-RAGE-centered experimental model of diabetic vascular dysfunction.⁴

When high-glucose culture is used, appropriate controls should also be considered because increasing glucose concentration can alter medium osmolarity in addition to changing glucose availability.

Model Selection

Choosing Cell Models for Cardiovascular Research

Cell selection should follow the biological question rather than treating every cardiovascular cell system as interchangeable.

Endothelial Cells

Particularly useful for investigating vascular barrier function, inflammation, leukocyte adhesion, angiogenesis, metabolic dysfunction and responses to hemodynamic stress.

Examples: HAEC, HCAEC, HUVEC, cardiac microvascular ECs Research: Atherosclerosis, endothelial dysfunction, angiogenesis

Vascular Smooth Muscle Cells

Support investigation of contractile-to-synthetic phenotype changes, proliferation, migration, vascular remodeling, inflammatory signaling and pathological calcification.

Examples: Aortic and coronary artery VSMCs Research: Hypertension, atherosclerosis, vascular calcification

Monocytes & Macrophages

Useful for vascular inflammation, monocyte recruitment, macrophage differentiation, modified-lipoprotein uptake and foam-cell biology.

Examples: Primary monocytes, THP-1-derived macrophages Research: Atherosclerosis and inflammatory vascular disease

Cardiac Fibroblasts

Enable controlled analysis of TGF-β signaling, fibroblast activation, myofibroblast differentiation, collagen production and extracellular matrix remodeling.

Examples: Primary, finite-lifespan or immortalized cardiac fibroblasts Research: Fibrosis, remodeling and heart failure mechanisms

Cardiomyocytes

Appropriate for myocardial injury, contractile biology, cellular metabolism, calcium handling, electrophysiology and cardiovascular drug-safety studies.

Examples: Primary cardiomyocytes, hiPSC-CMs, selected cardiac cell lines Research: Ischemia, cardiomyopathy and cardiotoxicity

Engineered & iPSC-Derived Models

Gene knockout, overexpression, mutation and reporter strategies can isolate target-specific mechanisms. Patient-specific or engineered iPSC-derived cardiovascular cells can additionally support genetic disease modeling and precision pharmacology.

Examples: KO, OE, reporter, point-mutant and isogenic models Research: Target validation, inherited disease and drug response

Experimental Design

Reconstructing the Cardiovascular Microenvironment

Increasing biological complexity is useful when it answers a specific experimental question—not simply because a model contains more components.

Level 1

Single Cell Type

A defined cell population provides a controlled background for studying direct target biology, pathway activation and stimulus-response relationships.

Mechanistic resolution

Level 2

Disease-Associated Challenge

High glucose, AGE preparations, oxLDL, Ang II, hypoxia, cytokines, TGF-β or other stimuli can reproduce selected components of pathology.

Disease-like phenotype

Level 3

Combined Stress

Multiple variables can be incorporated when interactions between metabolic, inflammatory, mechanical or ischemic factors are central to the research question.

Context-dependent response

Level 4

Co-culture

Endothelial–immune, endothelial–VSMC, cardiomyocyte–fibroblast or other multicellular systems enable investigation of intercellular signaling.

Cell–cell interaction

Level 5

Advanced Human Models

iPSC-derived systems, 3D cardiac tissues and microphysiological models can incorporate human genetics, multicellular organization, mechanical loading or perfusion.

Higher physiological relevance

Experimental principle

A more complex model is not automatically a better model. The appropriate system is the one that reproduces the biological variables necessary to answer the intended research question while retaining sufficient experimental control and reproducibility.

From Mechanism to Intervention

Applying Cardiovascular Cell Models to Therapeutic Research

Mechanism Investigation

Identify signaling pathways, metabolic changes and cellular interactions responsible for disease-associated phenotypes.

Target Validation

Use genetic or pharmacological perturbation to test whether candidate targets causally regulate vascular or cardiac dysfunction.

Therapeutic Screening

Evaluate compounds for anti-inflammatory, anti-fibrotic, vascular-protective or cardioprotective activity in defined cellular systems.

Cardiovascular Safety

Investigate unintended effects on cardiomyocyte viability, metabolism, calcium handling, electrophysiology or contractile function.

Biomarker Discovery

Compare disease-associated and control states using transcriptomic, proteomic, secreted or functional endpoints.

Precision Disease Modeling

Incorporate patient-derived or genetically engineered cells to investigate genotype-dependent disease mechanisms and therapeutic responses.

Research Resources

Explore Cell Models for Cardiovascular Research

Different experimental questions may require primary cells for physiological relevance, immortalized models for reproducibility and scale, or engineered models for target-specific investigation.

Cell Models

Primary Cells

Explore primary endothelial cells, vascular cells, fibroblasts, immune cells and other physiologically relevant cell populations.

Browse Primary Cells → Cell Models

Immortalized Cells

Extended-lifespan cell models can support reproducible mechanistic studies, assay development and experiments requiring larger cell numbers.

Browse Immortalized Cells → Engineered Models

Genome-Edited Cells

Explore knockout, overexpression, reporter and other engineered models for target validation and pathway-focused cardiovascular research.

Browse Engineered Cells → Model Selection

Need a Specific Cardiovascular Model?

Contact our team to discuss cell type, species, target, genetic modification or experimental application requirements.

Scientific Literature

References

Selected literature supporting the research mechanisms and experimental examples discussed on this page.

1
World Health Organization. Cardiovascular diseases (CVDs). Updated July 31, 2025. WHO
2
Pasut A, Lama E, Van Craenenbroeck AH, et al. Endothelial cell metabolism in cardiovascular physiology and disease. Nature Reviews Cardiology. 2025;22:923–943. doi:10.1038/s41569-025-01162-x
3
Tamargo IA, Baek KI, Kim Y, et al. Flow-induced reprogramming of endothelial cells in atherosclerosis. Nature Reviews Cardiology. 2023;20:738–753. doi:10.1038/s41569-023-00883-1
4
Banarjee R, Sharma A, Bai S, Deshmukh A, Kulkarni MJ. Proteomic study of endothelial dysfunction induced by AGEs and its possible role in diabetic cardiovascular complications. Journal of Proteomics. 2018;187:69–79. doi:10.1016/j.jprot.2018.06.009
5
Patibandla PK, Rogers AJ, Giridharan GA, Pallero MA, Murphy-Ullrich JE, Sethu P. Hyperglycemic arterial disturbed flow niche as an in vitro model of atherosclerosis. Analytical Chemistry. 2014;86(21):10948–10954. doi:10.1021/ac503294p
6
Das S, Zhang E, Senapati P, et al. A novel angiotensin II-induced long non-coding RNA Giver regulates oxidative stress, inflammation, and proliferation in vascular smooth muscle cells. Circulation Research. 2018. PubMed Central
7
Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. Journal of the American Society of Nephrology. 2004;15(11):2857–2867. doi:10.1097/01.ASN.0000141960.01035.28
8
Wen J, Wang D, Cheng L, et al. The optimization conditions of establishing an H9c2 cardiomyocyte hypoxia/reoxygenation injury model based on an AnaeroPack System. Cell Biology International. 2021;45(4):757–765. doi:10.1002/cbin.11513
9
Cho N, Razipour SE, McCain ML. TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts. Experimental Biology and Medicine. 2018;243(7):601–612. doi:10.1177/1535370218761628
10
Chen IY, Matsa E, Wu JC. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nature Reviews Cardiology. 2016;13:333–349. doi:10.1038/nrcardio.2016.36
11
Burridge PW, Li YF, Matsa E, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine. 2016;22(5):547–556. doi:10.1038/nm.4087

References are provided for scientific context and representative experimental approaches. Selection of a cell model, stimulus, treatment concentration, exposure duration and assay endpoint should be optimized for the specific research question and experimental system.

Cardiovascular Disease Research

Cardiovascular Disease Research

Investigating Cardiovascular Disease Through Cellular Mechanisms

Cellular Processes Central to Cardiovascular Research

Endothelial Dysfunction & Vascular Homeostasis

Research Questions

Representative Models

Common Readouts

Lipid Handling, Vascular Inflammation & Foam-Cell Biology

Combining metabolic and hemodynamic stress

Vascular Smooth Muscle Phenotype, Remodeling & Calcification

Vascular Remodeling

Vascular Calcification

Cell-mediated vascular calcification

Ischemia, Hypoxia & Reperfusion Injury

Optimizing a hypoxia/reoxygenation cell model

Fibroblast Activation, Myocardial Fibrosis & Heart Failure

Chemical and mechanical regulation of human cardiac fibroblasts

Genetic Cardiovascular Disease, Engineered Models & Cardiotoxicity

Genetic Disease Modeling

Cardiovascular Safety

Patient-specific susceptibility to doxorubicin cardiotoxicity

From Cardiovascular Risk to Measurable Cellular Dysfunction

High glucose and AGEs represent related but different experimental questions.

Choosing Cell Models for Cardiovascular Research

Endothelial Cells

Vascular Smooth Muscle Cells

Monocytes & Macrophages

Cardiac Fibroblasts

Cardiomyocytes

Engineered & iPSC-Derived Models

Reconstructing the Cardiovascular Microenvironment

Single Cell Type

Disease-Associated Challenge

Combined Stress

Co-culture

Advanced Human Models

Applying Cardiovascular Cell Models to Therapeutic Research

Mechanism Investigation

Target Validation

Therapeutic Screening

Cardiovascular Safety

Biomarker Discovery

Precision Disease Modeling

Explore Cell Models for Cardiovascular Research

Primary Cells

Immortalized Cells

Genome-Edited Cells

Need a Specific Cardiovascular Model?

References

Reach Us Questions? Click Me Here!

🎁 Refer & Earn · Rewards for You & Your Friends

✨ Your Referral Link